Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2000
08/15/2000US6103733 Prevention of atherosclerosis and coronary heart disease; selective induction of hepatic cylochrome p450iiia (cyp3a) activity triphenylmethyl imidazoles or ppyridine substituted by a chlorine or fluorine
08/15/2000US6103721 Heteroaryl-substituted pyridazino quinoline compounds
08/15/2000US6103513 Novel proteolytic enzyme; for the treatment of immune, proliferative and degratory defects
08/15/2000US6103242 Treating diabetes in a patient
08/15/2000US6102254 Pharmaceutical compositions in semisolid form and a device for administration thereof
08/15/2000CA2148671C Stable crystalline (6s)-and (6r)-tetrahydrofolic acid
08/15/2000CA2062735C Novel methylenebisphosphonic acid derivatives
08/10/2000WO2000046351A2 Platform for the differentiation of cells
08/10/2000WO2000046240A2 Polypeptides involved in immune response
08/10/2000WO2000046214A1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
08/10/2000WO2000046209A1 Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
08/10/2000WO2000046204A1 Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same
08/10/2000WO2000046194A1 Cyclic amine derivatives and uses thereof
08/10/2000WO2000045846A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
08/10/2000WO2000045837A1 Novel use within transplantation surgery
08/10/2000WO2000045835A1 Vascular endothelial growth factor-2
08/10/2000WO2000045819A1 Use of cholesterol-lowering agent
08/10/2000WO2000045818A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
08/10/2000WO2000045817A1 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
08/10/2000WO2000045816A1 Calcilytic compounds
08/10/2000WO2000045809A1 L-arginine based formulations for treating diseases and methods of using same
08/10/2000WO2000045791A2 Method for controlling liposome size
08/10/2000WO2000045770A2 Compressed lecithin preparations
08/10/2000WO2000045649A1 Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
08/10/2000WO2000045648A1 Method of preparing microparticles of phytosterols or phytostanols
08/10/2000WO2000024911A3 Human phospholipases
08/10/2000WO2000024360A3 Preparation and use of solidified oils
08/10/2000WO2000021525A3 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
08/10/2000WO2000013706A8 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
08/10/2000WO2000010545A3 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
08/10/2000DE19904710A1 Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical compositions containing them
08/10/2000CA2362126A1 B7rp-1 polypeptides
08/10/2000CA2362077A1 Cyclic amine derivatives and uses thereof
08/10/2000CA2361805A1 Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same
08/10/2000CA2361615A1 The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
08/10/2000CA2361589A1 Calcilytic compounds
08/10/2000CA2361575A1 L-arginine based formulations for treating diseases and methods of using same
08/10/2000CA2361551A1 Method for controlling liposome size
08/10/2000CA2361539A1 Compressed lecithin preparations
08/10/2000CA2361437A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
08/10/2000CA2360835A1 Method of preparing microparticles of phytosterols or phytostanols
08/10/2000CA2359821A1 Platform for the differentiation of cells
08/10/2000CA2358641A1 Use of cholesterol-lowering agent
08/09/2000EP1026149A1 Amidocarboxylic acid derivatives
08/09/2000EP1025125A1 Aggregates of human insulin derivatives
08/09/2000EP1025106A2 Allosteric adenosine receptor modulators
08/09/2000EP1025102A1 Bicyclic kinase inhibitors
08/09/2000EP1025100A1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
08/09/2000EP1025096A1 Substituted chroman derivatives
08/09/2000EP1025095A1 Substituted chroman derivatives
08/09/2000EP1025094A1 Substituted indan derivatives
08/09/2000EP1025082A1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
08/09/2000EP1024819A1 Citrus peel extract as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
08/09/2000EP1024804A1 Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels
08/09/2000EP1024801A2 Method for regulating size and growth of vascularized normal tissue
08/09/2000EP1024701A1 Methods and compositions for the treatment of autoimmune disease using heat shock proteins
08/09/2000EP0642519B1 Sulfur-containing phosponate compounds for treating abnormal calcium and phosphate metabolism
08/09/2000EP0641201B1 Renewal of extrinsic aging of the skin by transdermal application of selenoamino acids
08/09/2000CN1262680A 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
08/09/2000CN1262675A (+)-Norcisapride useful for 5-HT3 and 5-HT4 mediated disorbers
08/09/2000CN1262627A Composition
08/09/2000CN1262267A 20 kinds of modified vitamin D series derivatives, preparing and drug thereof
08/08/2000US6100376 A21, B30, modified insulin derivatives having an altered action profile
08/08/2000US6100294 For treatment of metabolic, glandular, and bone disorders caused by vitamin deficiency
08/08/2000US6100275 8-azabicyclo[3.2.1.]oct-2-ene derivatives, their preparation and use
08/08/2000US6100251 Chromium polynicotinate compositions
08/08/2000US6100250 Enteric-coated chromium polynicotinate compositions and uses thereof
08/08/2000US6100090 Compound 8 to 30 nucleobases in length targeted coding region of human phosphatidyl inositol 3'-kinase p85; therapy and diagnosis of diseases related hormone and growth factor receptors and oncogene products
08/08/2000US6100048 Using a panel of mammalian cells transformed with recombinant expression constructs encoding a variety of melanocortin receptors; contacting cells with compound, detecting binding, and determing if compound inhibits feeding behavior
08/08/2000US6100037 Polynucleotide encoding a cyclic nucleotide phosphodiesterase having a specific amino acid sequence; diagnosis, treatment, and prevention of cancer and immune disorders; anticarcinogenic/antidiabetic/antiarthritic agents
08/08/2000US6099859 Controlled release oral tablet having a unitary core
08/08/2000US6099837 Pharmaceutical preparation for treating blood coagulation disorders
08/08/2000CA2219795C Modulation of cholesteryl ester transfer protein (cetp) activity
08/08/2000CA2185019C Isoxazoline compounds as inhibitors of tnf release
08/08/2000CA2177743C New alkoxy-aryl compounds, process for preparing the same and pharmaceutical compositions containing them
08/08/2000CA2017066C Azaindenes
08/03/2000WO2000044901A1 Transcriptional regulation of the human beta3-adrenergic receptor gene
08/03/2000WO2000044888A2 Dimethylarginine dimethylaminohydrolases
08/03/2000WO2000044863A1 Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof
08/03/2000WO2000044862A1 Process of converting rendered triglyceride oil from marine sources into bland, stable oil
08/03/2000WO2000044757A1 Hesperitin pro-forms with enhanced bioavailability
08/03/2000WO2000044753A1 Pirazino(aza)indole derivatives
08/03/2000WO2000044750A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
08/03/2000WO2000044749A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
08/03/2000WO2000044740A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044737A1 Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
08/03/2000WO2000044730A1 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/03/2000WO2000044721A1 3,7-disubstituted indole derivatives and medicinal compositions containing the same
08/03/2000WO2000044716A1 Acetylenic sulfonamide thiol tace inhibitors
08/03/2000WO2000044711A1 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044709A2 ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044707A1 Novel substituted guanidine derivatives and process for the preparation thereof
08/03/2000WO2000044400A1 Treatment for diabetes
08/03/2000WO2000044391A2 Plasminogen kringle 4 region fragments and methods of use
08/03/2000WO2000044388A1 Modulation of immune response by ribavirin
08/03/2000WO2000044382A1 Composition and method for treating diabetes
08/03/2000WO2000044374A1 Use of anticonvulsant derivatives for treating bulimia nervosa
08/03/2000WO2000044371A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000WO2000044350A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000WO2000037062A3 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
1 ... 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 ... 1298